HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro.

AbstractPURPOSE:
The fibrinolytic system is involved in a wide variety of biological phenomena and differs physiologically in newborns compared to older children or adults. Because the newborn has hypoplasminogenemia and a possible existence of a dysfunctional plasminogen with normal adult levels of plasminogen activator inhibitor type 1 and alpha 2-antiplasmin and elevated levels of plasminogen activator inhibitor type 2, it could be expected that the response to standard concentrations and doses of plasminogen activators would be reduced.
PATIENTS AND METHODS:
We have studied the kinetics of in vitro fibrinolysis after adding different concentrations of streptokinase(SK), urokinase(UK), and recombinant tissue plasminogen activator(rt-PA) by use of a microtiter clot lysis assay.
RESULTS:
Geometrical dilution rows showed characteristic dose response curves. After clot formation a rapid lysis was seen with all plasminogen activators. The 50% lysis time correlated to the plasminogen activator dose and showed no differences among normal adults, children aged 1-6 years, and children age 7-14 years. Newborns demonstrated a significantly prolonged 50% lysis time with all urokinase concentrations. The 50% lysis time with recombinant tissue plasminogen activator and streptokinase was significantly prolonged only at high concentrations, whereas we could not see any differences at lower concentrations.
CONCLUSION:
The experience with thrombolytic agents in newborns is limited, and no controlled investigations have been reported. Our results of the fibrinolytic potential in a plasma milieu in vitro after adding different plasminogen activators can be helpful to establish dosage guidelines for thrombolytic therapy in newborns and older children.
AuthorsM Ries, M Zenker, J Klinge, H Keuper, D Harms
JournalJournal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 17 Issue 3 Pg. 260-4 (Aug 1995) ISSN: 1077-4114 [Print] United States
PMID7620925 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Recombinant Proteins
  • Streptokinase
  • Plasminogen Activators
  • Urokinase-Type Plasminogen Activator
Topics
  • Adolescent
  • Adult
  • Age Factors
  • Child
  • Child, Preschool
  • Fibrinolysis (drug effects)
  • Humans
  • In Vitro Techniques
  • Infant, Newborn
  • Plasminogen Activators (pharmacology)
  • Platelet Aggregation (drug effects)
  • Recombinant Proteins (pharmacology)
  • Streptokinase (pharmacology)
  • Urokinase-Type Plasminogen Activator (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: